Home Blog Page 227
CombiMatrix
CombiMatrix, a CLIA-certified laboratory, is bringing microarray analysis to the underserved problem of recurrent pregnancy loss as well as to prenatal testing. CombiMatrix performs microarray assays that deliver more complete results faster than traditional lab tests. “Between 50% and 60% of all recurrent miscarriages are caused by a chromosomal abnormality,” Mark McDonough, president and CEO, says. To determine whether a...
Researchers at Keele University have developed SIFT-MS
Clinical applications for mass spectrometry technology have exploded in recent years. Mass spectrometry analysis is often faster, cheaper, and more sensitive than other methods and is thus ideally suited for both diagnostics and therapeutic monitoring. “Mass spectrometry is finally being accepted by microbiologists as a powerful analytical tool and is currently revolutionizing diagnostics,” says Haroun Shah, Ph.D., head of the...
Using frozen tissue remains the method of choice for characterizing the genome
Biobanking, already a critical resource for bioresearch and medicine, is becoming even more important. According to a forecast prepared by BCC Research, biobanking will represent a $183 billion worldwide market by 2015. Besides rising in value, biobanking is growing more complicated. Questions of science, ethics, administration, and business viability are all part of biobanking’s dynamic landscape. Multiple stakeholders including...

The tenth issue of Clinical OMICs is available now! Check it out by clicking on the link below.

Source: © Picture Partners - Fotolia.com
How may far-separated objects quickly come into proximity and directly influence each other? In this universe, wormholes are just the thing, at least on the very largest scales. When space curves upon itself, once-distant locations may intersect, say cosmologists and sci-fi gurus, making the universe a more interesting place—one needn’t take light years to traverse unimaginably vast stretches of...
Source: © Mopic - Fotolia.com
Thermo Fisher Scientific completed the listing of its Ion PGM Dx next-generation sequencing (NGS) system with the FDA for clinical use as a class II medical device. Intended for targeted sequencing of human genomic DNA using peripheral whole-blood samples, the system supports the development and implementation of user-defined NGS diagnostic assays in a clinical laboratory and enables 21 CFR Part...
Source: © Paolese - Fotolia.com
Researchers at Northwestern Medicine say they have developed the first blood test to diagnose major depression in adults. The assay, which works by measuring the levels of nine RNA blood markers, also predicts who will benefit from cognitive behavioral therapy based on the behavior of some of the markers. In addition, the test showed the biological effects of cognitive behavioral...
Source: © Francois du Plessis - Fotolia.com
September is newborn screening awareness month. Since 1963, state public health programs have screened newborns for a number of life-altering health conditions. Many of these disorders are rare and genetic, and if caught in the first weeks of life they can be treated or managed to prevent death or a lifetime of disability. Early detection can also help families...
Single-gene testing just isn't adequate anymore
There are huge benefits to genomic tumor assessment, both for better treatment now, and later, if first-line treatments fail. But I don’t think many cancer patients—and even some physicians—fully understand how important tumor sequencing can be to successful cancer treatment. Yet. This is not surprising. Outside of a few tests for breast cancer, we really didn’t have the tools to...
With the issuance of this new framework
In 1992, the Food and Drug Administration (FDA) first stated that it had authority to regulate laboratory-developed tests. On July 31, FDA took its biggest step toward invoking this asserted authority by unveiling its “Framework for Regulatory Oversight of Laboratory-Developed Tests (LDTs).” In the framework, FDA explains that while it had traditionally exercised enforcement discretion and not regulated LDTs, due...
Scroll Up